POTENTIAL BENEFIT OF CURCUMIN ADJUVANT THERAPY TO THE STANDARD H. PYLORI ERADICATION THERAPY IN PATIENTS WITH PEPTIC ULCER DISEASE
Objective: This study was designed to explore the benefit of curcumin as adjuvant therapy to the standard H pylori eradication triple therapy in both duodenal and gastric ulcers patients.Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â
Methods: The present study enrolled 40 patients newly diagnosed endoscopically with peptic ulcer disease to be allocated into group1 treated with standard H. pylori eradication triple therapy, and group2 patients treated with curcumin (500mg) capsules three times daily for 14 day as adjuvant to standard triple therapy. Stool antigen test, immunoglobulin M serology test, tumor necrosis factor-alpha (TNF-Î±), interleukin 1 beta (IL1Î²), and total antioxidant capacity (T-AOC) are measured at the baseline and after 6 weeks of treatment.
Results: The result showed that theÂ use of curcumin as adjuvant therapy produced highly significant improvement in healing efficacy which was significantly distinguished Â in duodenal ulcer patients compared to gastric ulcer groups 2 patients (p <0.05), along with highly significant reduction in pro inflammatory IL1Î² level in group 2 patients(p<0.01). After 6 weeks of treatment there was highly significant elevation in level of TNF- Î± in groups 1 (p value <0.01), though, group 2 patients presented with non significant elevation in TNF-Î± level. Moreover, the total antioxidant capacity was improved with curcumin adjuvant therapy, though non- significant, compared to group 1patients who showed reduction in total antioxidant capacity.
Conclusion: This study revealed that addition of curcumin as adjuvant therapy produced improvement in ulcer healing efficacy, and controlled the inflammatory and oxidative stress process induced by H pylori infection.
Terminalia arjuna bark. Int J Pharm Pharm Sci 2012;4(3):203-5.
2. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev 2006;19(3):449-90.
3. Verbeke H, Geboes K, Van Damme J, Struyf S. The role of CXC chemokines in the transition of chronic inflammation to esophageal and
gastric cancer. Biochim Biophys Acta 2012;1825(1):117-29.
4. Zaidi SF, Ahmed K, Yamamoto T, Kondo T, Usmanghani K, Kadowaki M, et al. Effect of resveratrol on Helicobacter pyloriinduced
interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. Biol Pharm
5. De R, Kundu P, Swarnakar S, Ramamurthy T, Chowdhury A, Nair GB, et al. Antimicrobial activity of curcumin against Helicobacter pylori
isolates from India and during infections in mice. Antimicrob Agents Chemother 2009;53(4):1592-7.
6. Fashner J, Gitu AC. Diagnosis and treatment of peptic ulcer disease and H. pylori infection. Am Fam Physician 2015;91(4):236-42.
7. Xie JH, Chen YL, Wu QH, Wu J, Su JY, Cao HY, et al. Gastroprotective and anti-Helicobacter pylori potential of herbal formula HZJW: Safety
and efficacy assessment. BMC Complement Altern Med 2013;13:119.
8. Nimmi OS, George P. Evaluation of the antioxidant potential of a newly developed polyherbal formulation for antiobesity. Int J Pharm Pharm Sci 2012;4(3):205-10.
9. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: A review of preclinical and clinical
research. Altern Med Rev 2009;14(2):141-53.
10. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: Problems and promises. Mol Pharm
11. Balachandran P, Govindarajan R. Cancer - An ayurvedic perspective. Pharmacol Res 2005;51(1):19-30.
12. Kewitz S, Volkmer I, Staege MS. Curcuma contra cancer? Curcumin and hodgkinâ€™s lymphoma. Cancer Growth Metastasis 2013;6:35-52.
13. Mei X, Xu D, Wang S, Xu S. Pharmacological researches of curcumin solid dispersions on experimental gastric ulcer. Zhongguo Zhong Yao Za Zhi 2009;34(22):2920-3.
14. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (Diferuloylmethane) induces apoptosis through activation of caspase-8,
BID cleavage and cytochrome c release: Its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis 2002;23(1):143-50.
15. Fuccio L, Eusebi LH, Bazzoli F. Gastric cancer, Helicobacter pylori infection and other risk factors. World J Gastrointest Oncol
16. Alakkari A, Zullo A, Oâ€™Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter 2011;16 Suppl 1:33-7.
17. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: Duration of first-line proton-pump inhibitor based
triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007;147(8):553-62.
18. Vaira D, Zullo A, Vakil N, Gatta L, Ricci C, Perna F, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori
eradication: A randomized trial. Ann Intern Med 2007;146(8):556-63.
19. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, et al. 14-Day triple, 5-day concomitant, and 10-day
sequential therapies for Helicobacter pylori infection in seven Latin American sites: A randomised trial. Lancet 2011;378(9790):507-14.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.